Chen, W.-T
Tepezza, Tezspire growing Key Peptide Products: MariTide (maridebart cafraglutide GLP-1R agonist/GIPR antagonist peptide-antibody conjugate, Phase 2/3 pipeline for obesity), Nplate (romiplostim Fc-peptide fusion for ITP), Tezspire (tezepelumab, with AstraZeneca), Aimovig (erenumab CGRP receptor mAb for migraine) Therapeutic Segments: General Medicine (Repatha, Aimovig, Otezla)
Theres excitement about its potential impact on cholesterol, fatty liver, and heart health, which adds layers to its value in the clinic
Among patients without diabetes, the pattern differed from patients with type 2 diabetes: patients on a GLP-1 who maintained a stable weight had a higher osteoporosis risk relative to those who maintained a stable weight on another weight loss medication (22.0% higher for GLP-1 users)
Site map Privacy Notices Terms Contact us Language assistance / non-discrimination Asistencia de idiomas / Aviso de no discriminacin / Accessibility Your Privacy Choices Quest is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies